Our study included 339 fluoropyrimidine and thymidylate synthase inhibitor-resistant CRC patients, all treated uniformly at 350 mg m−2 of irinotecan once every 3 weeks and this represents the largest single study with second-line irinotecan monotherapy reported to our knowledge. The gene discussed is TYMS; the disease is colorectal carcinoma.